8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 5, 2021

ENOCHIAN BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

+1(786) 888-1685

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

On March 5, 2021, Enochian Biosciences Inc., a Delaware corporation (the “Company”), held its annual meeting of stockholders (the “Meeting”) as prescribed in the Proxy Statement filed by the Company with the Securities and Exchange Commission on February 3, 2021. At the Meeting, four proposals were submitted for a vote of the Company’s stockholders and the related results are as follows:

Proposal No. 1: The electionof Renè Sindlev, Mark R. Dybul, M.D., Carol L. Brosgart M.D, Gregg Alton, Evelyn D’An, James Sapirstein, Carl Sandlerand Henrik Gronfeldt-Sorensen. for terms until the next annual meeting of stockholders or until each such director’s successorshall have been duly elected and qualified. The stockholders elected each of the eight directors by the following votes:

Proposal No. 2: An advisory vote on the compensation paid to our named executive officers. The proposal was approved as follows*:*

Proposal No. 3: The approval of a non-binding resolutionregarding the frequency of future advisory votes on the compensation of the Company’s named executive officers. The stockholders approved the non-binding advisory resolution regarding the frequency of future votes on executive compensation with respect to every three (3) years as follows:

The Company has decided to set the frequency of future advisory votes on the compensation of the Company’s named executive officers at every three (3) years going forward.

Proposal No. 4: Ratificationof Independent Registered Public Accounting Firm. The stockholders ratified Sadler, Gibb & Associates, LLC as the Company’s independent registered public accounting firm as follows:

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 10, 2021

2